{'fraction_non_alphanumeric': 0.0160481444332999, 'fraction_numerical': 0.0050150451354062184, 'mean_word_length': 5.3164556962025316, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
LACK OF NEPHROTOXICITY OF DIMETHYL SULFOXIDE IN MAN AND LABORATORY ANIMALS

Abstract : Intravenous DMSO has been undergoing extensive clinical testing in the treatment of cerebral edema and other neurological disorders. During early therapeutic usage of 1 mg/kg as 10-40% solutions, intravascular hemolysis and hemoglobinuria were noted during the drug infusions. Since these processes have potential adverse effects on renal function, patients receiving this drug had careful observation of renal function before and after such infusions. In addition, the effects of similar doses of DMSO on a weight basis were assessed in Sprague-Dawley rats. Finally DMSO was superimposed on a standard model of nephrotoxic acute renal failure in order to assess any additive toxic effects. No short-term nephrotoxic effects on intravenous DMSO could be discerned in patients or laboratory animals despite hemoglobinuria. Intravenous DMSO is safe to use in patients who are prospective renal transplant donors.